2021 Year in Review - Multiple Myeloma
2021 Year in Review - Multiple Myeloma | February 23, 2022
Initial primary analysis results of the ongoing phase 3 GMMG-HD7 trial demonstrated that the addition of isatuximab to the standard-of-care RVd regimen was associated with superior MRD negativity rates after induction, and the regimen was not accompanied by emergence of new safety signals or early discontinuation.
2021 Year in Review - Multiple Myeloma | February 23, 2022
The International Myeloma Working Group developed evidence-based clinical practice recommendations for the treatment of RRMM, with the goal to help guide real-world clinical practice and improve patient outcomes.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Longer-term data from the DREAMM-2 trial confirmed the sustained clinical activity of the anti–B-cell maturation antigen antibody–drug conjugate belantamab mafodotin in heavily pretreated patients with RRMM, with no emergence of new safety signals.
2021 Year in Review - Multiple Myeloma | February 23, 2022
These results indicate that quadruplet induction therapy with daratumumab plus carfilzomib, lenalidomide, and dexamethasone (D-KRd); ASCT; and MRD response–adapted D-KRd consolidation therapy yielded high MRD negativity rates in patients with NDMM.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Results of the 18-month follow-up of the phase 1b/2 CARTITUDE-1 trial indicated that a single infusion of cilta-cel produced early, deep, and durable responses in heavily pretreated patients with RRMM, with manageable toxicity.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Longer follow-up results of the phase 2 GRIFFIN trial demonstrated that the addition of daratumumab to RVd induction/consolidation in conjunction with ASCT, followed by 24 months of daratumumab-lenalidomide maintenance resulted in deep and durable responses, including stringent CR and MRD negativity rates, in patients with transplant-eligible NDMM.
